Last Updated: 11/06/2026

Immunocore

Oxford

Founded 2008

TCR bispecific immunotherapies for cancer and infectious disease

Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies.

Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025.

Three Phase 3 trials are enrolling across melanoma indications, with topline data expected from 2026.

The broader pipeline spans PRAME-targeting oncology programmes, HIV and hepatitis B functional cure candidates, and autoimmune disease programmes.

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Member of